Plain-English translation of NCT06569524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing TQA2225/AP025, a new medication designed to treat nonalcoholic steatohepatitis (NASH), a condition where fat builds up in the liver and causes damage. Researchers want to see if this medication can reduce liver fat and improve liver health in adults with this condition. You would receive either the medication or a placebo (a dummy injection with no active drug) as weekly shots under your skin for about a year.
Currently, there are very few effective treatments for fatty liver disease. This medication works differently than existing options, and researchers hope it could help reduce liver inflammation and scarring while slowing disease progression.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly over 48 weeks to receive weekly injections under your skin of either the new medication or a placebo. You would also have blood tests, liver imaging scans, and possibly a liver biopsy to measure how the treatment is working. The study is double-blind, meaning neither you nor the researchers will know whether you're receiving the active medication or a placebo until the study ends.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China